Quantcast
Last updated on April 24, 2014 at 16:36 EDT

Latest Genentech Stories

2012-10-30 11:25:39

IRVINE, Calif., Oct. 30, 2012 /PRNewswire/ -- GeneTex Inc., a leading manufacturer of antibodies and antibody-related reagents, will be attending the annual meeting of the America Society for Cell Biology (ASCB) from December 15-19 in San Francisco, CA. The ASCB was founded in 1960 as an inclusive community of cell biologists and is dedicated to advancing scientific discovery, advocating sound research policies, improving education, promoting professional development and promoting diversity...

2012-10-26 04:03:09

NCM USA announced today it has signed a Technology Development and Supply Agreement with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), for the development of specialty clinical imaging agents using Zr-89 developed by NCM USA. New York, NY (PRWEB) October 25, 2012 NCM USA announced today it has signed a Technology Development and Supply Agreement with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), for the development of specialty clinical imaging...

2012-09-24 02:26:40

NEW YORK, Sept. 24, 2012 /PRNewswire/ -- Ohr Pharmaceutical (OTCBB: OHRP-News) today announced the initiation of a Phase II clinical trial to evaluate the efficacy and safety of Squalamine Eye Drops for the treatment of the wet form of age-related macular degeneration ("wet-AMD"). The randomized, double blind, placebo controlled study will enroll patients at twenty one ophthalmology treatment centers across the United States. Interim results are expected in the fourth quarter of 2013. "An...

2012-09-18 06:29:07

BURLINGAME, Calif., Sept. 18, 2012 /PRNewswire/ -- Igenica, Inc., a leading biopharmaceutical company focused on the discovery and development of first-in-class cancer antibody therapeutics, today announced the appointment of Mary Haak-Frendscho, Ph.D., to the role of Chief Executive Officer and member of the Board of Directors. Dr. Haak-Frendscho succeeds David Goeddel, Ph.D., who remains as Igenica's Chairman of the Board. Dr. Haak-Frendscho brings more than twenty years of experience in...

2012-09-07 02:23:46

SAN DIEGO, Sept. 7, 2012 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced that Ted W. Love, M.D., has joined its Board of Directors. Dr. Love most recently served as Executive Vice President and Head of Research and Development and Technical Operations at Onyx Pharmaceuticals, Inc., where he launched four multi-center, global phase 3 studies in two years and played a key role in obtaining in 2012 accelerated approval from the FDA to market Kyprolis(TM)...

2012-09-06 02:30:59

INCLINE VILLAGE, Nev., Sept. 6, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced royalty revenue guidance for the third quarter ending September 30, 2012, of approximately $85 million, as compared with actual royalty revenue of $83 million for the third quarter of 2011, a two percent increase. (Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO) The forecasted growth in royalty revenues is driven by increased second quarter 2012 sales of...

2012-08-02 10:27:34

INCLINE VILLAGE, Nev., Aug. 2, 2012 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today reported financial results for the second quarter and six months ended June 30, 2012. (Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO) Royalty revenues for the second quarter of 2012 increased three percent to $125.9 million from $122.1 million reported in the second quarter of 2011. For the first six months of 2012, royalty revenues increased four percent to $203.2 million from...

2012-07-31 02:27:49

PENZBERG, Germany, July 31, 2012 /PRNewswire/ -- Roche and SynenTec today announced that Roche will transfer its Cellavista business to SynenTec, the German company which is the original inventor of the Cellavista System. This agreement was made as a result of the Roche Applied Science decision to focus its business, and guarantees future optimal support and development of the technology for its customers. The Cellavista Imaging System for noninvasively measuring cell...

2012-07-24 06:23:50

LIVONIA, Mich., July 24, 2012 /PRNewswire/ -- Genentech and Novartis have the best image among oncologists and hematologists, according to Market Strategies International, a market research consultancy that recently completed its 2012 Oncology Image Study. The study evaluated more than 30 attributes related to field force, corporate functions and R&D to determine which measures drive a company's image and performance in this rapidly growing, competitive marketplace. Genentech maintains...

2012-07-24 02:29:05

RALEIGH, N.C., July 24, 2012 /PRNewswire/ -- PRA, a leading Clinical Research Organization, announces that it is participating in a groundbreaking Alzheimer's disease study that could lead to treatments delaying or even preventing the emergence of symptoms in people destined to develop the disease because of their genetic background. The clinical trial is a collaborative effort involving the Banner Alzheimer's Institute (BAI); Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX:...